ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma
SALT LAKE CITY, July 20, 2026 /PRNewswire/ -- ARUP Laboratories today announced the launch of ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new assay will characterize small neoplastic populations with greater confidence and sensitivity than conventional flow...
SALT LAKE CITY, July 20, 2026 /PRNewswire/ -- ARUP Laboratories today announced the launch of ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new assay will characterize small neoplastic populations with greater confidence and sensitivity than conventional flow...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.